jeudi 26 mai 2011

Anticancer molecules (13) – Molécules anticancéreuses (13)

IBRITUMOMAB TIUXETAN

Name: ibritumomab tiuxetan

Commercial name: Zevalin

Pharmacological class:

Therapeutic class: antineoplastic

Action:

Ibritumomab tiuxetan is approved (2011):

● to treat certain types of B-cell non-Hodgkin lymphoma (NHL). It is used in patients who have been treated with chemotherapy or with rituximab alone and have not gotten better or have had a relapse. Ibritumomab tiuxetan is combined with a radioactive substance and given with rituximab, as a type of radioimmunotherapy.